Check the time stamp on this data. Updated AI-Generated Signals for Nurix Therapeutics Inc. (NRIX) available here: NRIX. Type ...

Investors in Nurix Therapeutics Inc (Symbol: NRIX) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

$NRIX insiders have traded $NRIX stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales. Here’s a ...

SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat ...

SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat ...

Check the time stamp on this data. Updated AI-Generated Signals for Nurix Therapeutics Inc. (NRIX) available here: NRIX. Type ...

Barclays analyst Peter Lawson maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $31.00.

Nurix Therapeutics (NRIX) focuses on protein degradation in cancer treatment, with a current valuation of $1.4 billion and promising early-stage clinical data. NX-5948, a BTK degrader, shows high ...

In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price ...

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report)‘s stock had its “overweight” rating restated by Stephens in a report issued on Tuesday,Benzinga reports. They currently have a $31.00 target price on ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like NX-5948. The company’s DELigase platform allows for targeted protein ...